Biochemical Assay Development Using Novel MALDI High-Throughput Screening System
This whitepaper focuses on developing biochemical assays where substrate and product are small molecules using a novel MALDI-HTS system…
Label-free detection methods based on mass spectrometry are gaining momentum in high-throughput screening (HTS) for pharmaceutical drug discovery.
Most of these mass spectrometry methods are centred on multiplexed LC-MS and SPE-MS. MALDI-TOF has an inherent advantage over multiplexed LC-MS and SPE-MS techniques by being 10-100 times faster. MALDI-TOF methods can also significantly reduce costs, the amount of solvent being used and the amount of chemical waste being generated.
This work focuses on developing biochemical assays where substrate and product are small molecules using a novel MALDI-HTS system.
This whitepaper is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Related content from this organisation
- Whitepaper: The Use of Positron Emission Tomography (PET) in Pre-clinical Pharmaceutical Research
- QA/QC & Analytical Techniques In-Depth Focus 2019 featuring Environmental Monitoring
- Quality assessment of biologics: higher order structure analysis using NMR
- Bruker introduces scimaX™ MRMS for novel phenomics workflows, and further enhances the timsTOF™ Pro for PASEF Proteomics at ASMS
- Bruker launches new FT-IR R&D Spectrometer INVENIO™